Also known as: kale leaves
Latest evidence update: 2024-10-26
Strongest in Sample size (78). Held back by Recency (32).
Solid mix of RCTs with some methodological gaps.
Good cross-study replication, some imprecision.
Tens of thousands of participants pooled across studies.
Mixed direction across studies.
Mostly pre-2020 research; updates may be needed.
No quantified outcomes yet. Once we have studies with measurable endpoints, you will see per-outcome magnitude here.
Compound-by-compound profile of what's in this food and the evidence behind each.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
Hypokalemia occurred in approximately 50% of patients receiving acetazolamide as an adjuvant to standard treatment.
Abiraterone acetate increases the risk of hypokalemia in patients with advanced prostate cancer compared to control.
The risk of hypokalemia with abiraterone acetate is greater when control group does not receive steroids (OR 6.88) compared to when control group receives steroids (OR 1.86).
Hypokalemia risk with abiraterone acetate is greater in patients with metastatic hormone-sensitive prostate cancer (mHSPC) compared to metastatic castration-resistant prostate cancer (mCRPC).
Patiromer may enable use of renin-angiotensin-aldosterone system inhibitors at optimal guideline-recommended doses in patients with hyperkalemia by reducing potassium levels.